Paradigm Biopharmaceuticals to present at the annual JP Morgan healthcare conference next week
The company is focused on the development of a Phase 3 clinical program for its Zilosul® treatment for osteoarthritis.
Company
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a drug repurposing company driven by core competencies and experience at board and executive level in clinical and commercial pharmaceutical development. The company’s approach is to take an existing approved drug, which has demonstrated safety in its approved indications, and repurposing the drug in a new patented therapeutic application. Paradigm’s pipeline indications cover the use of pharmaceutical compound Pentosan Polysulfate Sodium (PPS), supported by full patent and IP protection and its immediate commercial focus is the repurposing of PPS for the treatment of Osteoarthritis (OA).
175 stories · page 4 of 9
COVID-19 dominates 2020 for biotech sector … and everyone else
The coronavirus began the year as a mysterious virus limited to China but ended up the dominant biotech story of 2020.
Paradigm Biopharmaceuticals proceeding with IND submission for Zilosul® for osteoarthritis after positive FDA Type C meeting feedback
The same clinical trial protocol will be used in the US, Europe and Australia, potentially enabling registrations in multiple jurisdictions, saving time and money.
Paradigm Biopharmaceuticals adds IP expertise to board with Amos Meltzer appointed non-executive director
The company is continuing the search for a person with extensive financial experience who will also be added to the board as an independent non-executive director.
Paradigm Biopharmaceuticals to host first R&D presentation this month to update on Zilosul pipeline
The late-stage drug development company said the presentation would cover its proposed clinical program, safety and an update on other indications in the company’s R&D pipeline.
Paradigm Biopharmaceuticals initiates Mucopolysaccharidosis type I open label Phase II clinical trial with first patient dosed
The trial will be Paradigm’s first in MPS-I patients and will investigate treatment in a population, including pediatric patients.
Paradigm Biopharmaceuticals adds three new senior executives to its team
Commercial head Beverley Huttmann, chief financial officer Justin Cahill and R&D scientist Catherine Stapledon bring skills and experience that further strengthen the capabilities of management as the company moves toward commercialisation.
Paradigm Biopharmaceuticals data shows Zilosul reduces pain in patients with knee osteoarthritis
Pain reduction in 76 SAS patients (42 new patient data) being treated using the Phase 3 product are consistent with prior reports under TGA SAS.
Paradigm Biopharmaceuticals extends exclusive supply agreement with bene pharmaChem
The exclusive supply of Pentosan Polysulphate Sodium for 25 years following marketing approval provides a greater level of commercial protection for Paradigm as it progresses towards commercialisation of Zilosul® in Europe.
Paradigm Biopharmaceuticals has clear path towards Zilosul® OA Phase 3 clinical trial and product registration in Europe
Positive feedback has been received from European Medicines Agency after Paradigm’s recent Scientific Advice meeting, a key regulatory milestone which supports and validates the company’s clinical development and commercialisation plans for
Paradigm Biopharmaceuticals receives critical approvals and feedback from agencies to progress MPS
Paradigm’s investigation of PPS for MPS seeks to establish whether PPS may be an effective adjunct/combination therapy with current Enzyme Replacement Therapy treatments.
Paradigm Biopharmaceuticals higher on reporting 65% pain reduction in OA patients treated under US FDA EAP
Each Patient enrolled in the program was screened to measure their baseline pain scores under the WOMAC osteoarthritis index and evaluated with MRI scans.
Paradigm Biopharmaceuticals set to release results of FDA’s IND expanded access program for Zilosul osteoarthritis treatment
The company remains focused on its IND submission to the FDA for the remainder of 2020.
Paradigm Biopharmaceuticals adds medical and strategic experience to board with executive director appointment
Dr Donna Skerrett has more than 30 years in the pharmaceutical industry and has been the company's chief medical officer since September 2019.
Paradigm Biopharmaceuticals chairman tenders resignation
Paradigm is an Australian biopharmaceutical company focused on repurposing the drug pentosan polysulphate sodium (PPS) for the treatment of inflammation.
Paradigm Biopharmaceuticals strengthens team with additional clinical and commercial expertise
The company is preparing for phase-3 trials in both Osteoarthritis (OA) and Mucopolysaccharidosis (MPS).
Paradigm Biopharmaceuticals share register continues to globalise with upcoming catalysts
The company recently reported a 45% reduction in pain across 34 patients with knee osteoarthritis (OA) using its phase 3 clinical trial product Zilosul.
Pharma companies buck the trend to outshine other sectors in Asia-Pacific region
Businesses are bracing for a recession but data shows pharmaceutical companies are growing due to increased demand from healthcare providers.
Paradigm Biopharmaceuticals completes Zilosul dosing under FDA’s Expanded Access Program
Earlier this month, Paradigm reported a 45% mean reduction in pain score across 34 patients with knee osteoarthritis (OA) using Zilosul.
Paradigm Biopharmaceuticals has significant clarity on development pathway for Zilusol: Bell Potter
The recent market announcements and $35 million capital raise have provided significant clarity to numerous aspects of the company’s development pathway for Zilusol.